The novel class of GLP-1 agonist medication and GIP dual medications, such as tirzepatide, semaglutide, and the newly introduced retatrutide, provide significant progress in diabetes management . Despite https://semaglutide649379.stilblogger.com/921737/semaglutide-the-comparative-examination